Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CDC42 | P60953 | 1/20 | 0.60 |
| ▸ | RAC1 | P63000 | 1/20 | 0.60 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122373 | 1.00 | ACHE (0.61) | ACHEAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL14032691 | 1.00 | ACHE (0.61) | ACHEAKR1C3AKR1C2PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL3225395 | 0.98 | ACHE (0.59) | ACHEAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL16867628 | 0.89 | ACHE (0.53) | ACHEAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL19365873 | 0.89 | ACHE (0.53) | ACHEAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL16867623 | 0.89 | ACHE (0.53) | ACHEAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL3673327 | 0.87 | HIF1A (0.59) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL8193391 | 0.87 | ACHE (0.54) | ACHEPTGS2TSHRCYP1A2HIF1A | |
| SCHEMBL7995934 | 0.86 | HIF1A (0.57) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL7995945 | 0.86 | HIF1A (0.57) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118388355-A | Method for preparing dopamine hydrochloride intermediate | 山东达冠医药科技有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-112409974-B | Amphiphilic bio-based degradable underwater adhesive and preparation method and application thereof | 江南大学 | 2021-12-21 | — | — | CN | claimed |
| CN-112409974-A | Amphiphilic bio-based degradable underwater adhesive and preparation method and application thereof | 江南大学 | 2021-02-26 | — | — | CN | claimed |
| EP-4734977-A2 | NOVEL TRPV1 AGONISTS AND USES THEREOF | Neucures, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006675-A9 | NOVEL TRPV1 AGONISTS AND USES THEREOF | NEUCURES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250059219-A1 | LIGNAN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-02-20 | — | — | US | disclosed |
| WO-2025006675-A2 | NOVEL TRPV1 AGONISTS AND USES THEREOF | NEUCURES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-118388355-A | Method for preparing dopamine hydrochloride intermediate | 山东达冠医药科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023160582-A1 | THIAZOLAMINE MBL INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学 | 2023-08-31 | — | — | WO | disclosed |
| CN-116354823-A | Preparation method and application of compound | 武汉珈海智药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022222686-A1 | LIGNAN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2022-10-27 | — | — | WO | disclosed |
| WO-2002088096-A1 | COMPOUNDS INHIBITING CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-11-07 | — | — | WO | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| EP-1189897-A1 | ISOFLAVONE METABOLITES | G.J. Consultants Pty Ltd (AU) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
| WO-2000066576-A1 | ISOFLAVONE METABOLITES | G.J. CONSULTANTS PTY LTD (AU) | 2000-11-09 | — | — | WO | disclosed |
| EP-0386243-A1 | PLATINUM (II) COMPLEXES | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4954659-A | FOOD PRESERVATIVE | CHEMEX PHARMACEUTICALS, INC. (US) | 1990-09-04 | — | — | US | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059219-A1 | LIGNAN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | HADHA, HADHB, HADH | ACHE 2416/4885AKR1C3 807/4885AKR1C2 495/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | ACHE 4305/4885AKR1C3 175/4885AKR1C2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.